Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology

Area of Science:

• Oncology
• Pathology
• Gastroenterology

Background:

• Colorectal cancer staging (Dukes B) requires precise risk stratification for optimal treatment.
• Adjuvant chemotherapy decisions for Dukes B patients are often guided by prognostic models.
• The Petersen prognostic model is a tool for assessing risk in colorectal cancer.

Purpose of the Study:

• To determine which Dukes B colorectal cancer patients could benefit from chemotherapy using routine pathology.
• To evaluate the effectiveness of the Petersen prognostic model in identifying high-risk Dukes B patients.
• To compare the survival outcomes of high-risk Dukes B patients with Dukes C patients.

Main Methods:

• Retrospective analysis of 1625 Dukes B and 480 Dukes C colorectal cancer patients (1997-2000).
• Assessment of five-year survival rates based on collected colorectal pathology datasets.
• Investigation of the Petersen prognostic model's predictive accuracy and comparison of survival data.

Main Results:

• Only 23.3% of patients had complete data for the Petersen index.
• The Petersen index showed significant survival differences between high and low-risk colon and rectal cancer patients.
• Dukes B patients with high-risk features had lower survival than Dukes C patients with one positive node.

Conclusions:

• The Petersen index can differentiate risk in Dukes B colorectal tumors, but reporting gaps limit its utility.
• Patients with high-risk pathological features exhibit survival rates below the threshold for adjuvant therapy.
• Chemotherapy may be beneficial for Dukes B patients with identified high-risk features; improved pathology reporting is essential.